• Something wrong with this record ?

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

JF. Colombel, R. Panaccione, P. Bossuyt, M. Lukas, F. Baert, T. Vaňásek, A. Danalioglu, G. Novacek, A. Armuzzi, X. Hébuterne, S. Travis, S. Danese, W. Reinisch, WJ. Sandborn, P. Rutgeerts, D. Hommes, S. Schreiber, E. Neimark, B. Huang, Q. Zhou,...

. 2018 ; 390 (10114) : 2779-2789. [pub] 20171031

Language English Country Great Britain

Document type Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial

Persistent link   https://www.medvik.cz/link/bmc18010282
E-resources Online Full text

NLK ProQuest Central from 1992-01-04 to 3 months ago
Nursing & Allied Health Database (ProQuest) from 1992-01-04 to 3 months ago
Health & Medicine (ProQuest) from 1992-01-04 to 3 months ago
Family Health Database (ProQuest) from 1992-01-04 to 3 months ago
Psychology Database (ProQuest) from 1992-01-04 to 3 months ago
Health Management Database (ProQuest) from 1992-01-04 to 3 months ago
Public Health Database (ProQuest) from 1992-01-04 to 3 months ago

Links

PubMed 29096949
DOI 10.1016/s0140-6736(17)32641-7
Knihovny.cz E-resources

BACKGROUND: Biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein, have been recommended for monitoring patients with Crohn's disease, but whether their use in treatment decisions improves outcomes is unknown. We aimed to compare endoscopic and clinical outcomes in patients with moderate to severe Crohn's disease who were managed with a tight control algorithm, using clinical symptoms and biomarkers, versus patients managed with a clinical management algorithm. METHODS: CALM was an open-label, randomised, controlled phase 3 study, done in 22 countries at 74 hospitals and outpatient centres, which evaluated adult patients (aged 18-75 years) with active endoscopic Crohn's disease (Crohn's Disease Endoscopic Index of Severity [CDEIS] >6; sum of CDEIS subscores of >6 in one or more segments with ulcers), a Crohn's Disease Activity Index (CDAI) of 150-450 depending on dose of prednisone at baseline, and no previous use of immunomodulators or biologics. Patients were randomly assigned at a 1:1 ratio to tight control or clinical management groups, stratified by smoking status (yes or no), weight (<70 kg or ≥70 kg), and disease duration (≤2 years or >2 years) after 8 weeks of prednisone induction therapy, or earlier if they had active disease. In both groups, treatment was escalated in a stepwise manner, from no treatment, to adalimumab induction followed by adalimumab every other week, adalimumab every week, and lastly to both weekly adalimumab and daily azathioprine. This escalation was based on meeting treatment failure criteria, which differed between groups (tight control group before and after random assignment: faecal calprotectin ≥250 μg/g, C-reactive protein ≥5mg/L, CDAI ≥150, or prednisone use in the previous week; clinical management group before random assignment: CDAI decrease of <70 points compared with baseline or CDAI >200; clinical management group after random assignment: CDAI decrease of <100 points compared with baseline or CDAI ≥200, or prednisone use in the previous week). De-escalation was possible for patients receiving weekly adalimumab and azathioprine or weekly adalimumab alone if failure criteria were not met. The primary endpoint was mucosal healing (CDEIS <4) with absence of deep ulcers 48 weeks after randomisation. Primary and safety analyses were done in the intention-to-treat population. This trial has been completed, and is registered with ClinicalTrials.gov, number NCT01235689. FINDINGS: Between Feb 11, 2011, and Nov 3, 2016, 244 patients (mean disease duration: clinical management group, 0·9 years [SD 1·7]; tight control group, 1·0 year [2·3]) were randomly assigned to monitoring groups (n=122 per group). 29 (24%) patients in the clinical management group and 32 (26%) patients in the tight control group discontinued the study, mostly because of adverse events. A significantly higher proportion of patients in the tight control group achieved the primary endpoint at week 48 (56 [46%] of 122 patients) than in the clinical management group (37 [30%] of 122 patients), with a Cochran-Mantel-Haenszel test-adjusted risk difference of 16·1% (95% CI 3·9-28·3; p=0·010). 105 (86%) of 122 patients in the tight control group and 100 (82%) of 122 patients in the clinical management group reported treatment-emergent adverse events; no treatment-related deaths occurred. The most common adverse events were nausea (21 [17%] of 122 patients), nasopharyngitis (18 [15%]), and headache (18 [15%]) in the tight control group, and worsening Crohn's disease (35 [29%] of 122 patients), arthralgia (19 [16%]), and nasopharyngitis (18 [15%]) in the clinical management group. INTERPRETATION: CALM is the first study to show that timely escalation with an anti-tumour necrosis factor therapy on the basis of clinical symptoms combined with biomarkers in patients with early Crohn's disease results in better clinical and endoscopic outcomes than symptom-driven decisions alone. Future studies should assess the effects of such a strategy on long-term outcomes such as bowel damage, surgeries, hospital admissions, and disability. FUNDING: AbbVie.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010282
003      
CZ-PrNML
005      
20180418101327.0
007      
ta
008      
180404s2018 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S0140-6736(17)32641-7 $2 doi
035    __
$a (PubMed)29096949
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Colombel, Jean-Frederic $u Department of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: jean-frederic.colombel@mssm.edu.
245    10
$a Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial / $c JF. Colombel, R. Panaccione, P. Bossuyt, M. Lukas, F. Baert, T. Vaňásek, A. Danalioglu, G. Novacek, A. Armuzzi, X. Hébuterne, S. Travis, S. Danese, W. Reinisch, WJ. Sandborn, P. Rutgeerts, D. Hommes, S. Schreiber, E. Neimark, B. Huang, Q. Zhou, P. Mendez, J. Petersson, K. Wallace, AM. Robinson, RB. Thakkar, G. D'Haens,
520    9_
$a BACKGROUND: Biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein, have been recommended for monitoring patients with Crohn's disease, but whether their use in treatment decisions improves outcomes is unknown. We aimed to compare endoscopic and clinical outcomes in patients with moderate to severe Crohn's disease who were managed with a tight control algorithm, using clinical symptoms and biomarkers, versus patients managed with a clinical management algorithm. METHODS: CALM was an open-label, randomised, controlled phase 3 study, done in 22 countries at 74 hospitals and outpatient centres, which evaluated adult patients (aged 18-75 years) with active endoscopic Crohn's disease (Crohn's Disease Endoscopic Index of Severity [CDEIS] >6; sum of CDEIS subscores of >6 in one or more segments with ulcers), a Crohn's Disease Activity Index (CDAI) of 150-450 depending on dose of prednisone at baseline, and no previous use of immunomodulators or biologics. Patients were randomly assigned at a 1:1 ratio to tight control or clinical management groups, stratified by smoking status (yes or no), weight (<70 kg or ≥70 kg), and disease duration (≤2 years or >2 years) after 8 weeks of prednisone induction therapy, or earlier if they had active disease. In both groups, treatment was escalated in a stepwise manner, from no treatment, to adalimumab induction followed by adalimumab every other week, adalimumab every week, and lastly to both weekly adalimumab and daily azathioprine. This escalation was based on meeting treatment failure criteria, which differed between groups (tight control group before and after random assignment: faecal calprotectin ≥250 μg/g, C-reactive protein ≥5mg/L, CDAI ≥150, or prednisone use in the previous week; clinical management group before random assignment: CDAI decrease of <70 points compared with baseline or CDAI >200; clinical management group after random assignment: CDAI decrease of <100 points compared with baseline or CDAI ≥200, or prednisone use in the previous week). De-escalation was possible for patients receiving weekly adalimumab and azathioprine or weekly adalimumab alone if failure criteria were not met. The primary endpoint was mucosal healing (CDEIS <4) with absence of deep ulcers 48 weeks after randomisation. Primary and safety analyses were done in the intention-to-treat population. This trial has been completed, and is registered with ClinicalTrials.gov, number NCT01235689. FINDINGS: Between Feb 11, 2011, and Nov 3, 2016, 244 patients (mean disease duration: clinical management group, 0·9 years [SD 1·7]; tight control group, 1·0 year [2·3]) were randomly assigned to monitoring groups (n=122 per group). 29 (24%) patients in the clinical management group and 32 (26%) patients in the tight control group discontinued the study, mostly because of adverse events. A significantly higher proportion of patients in the tight control group achieved the primary endpoint at week 48 (56 [46%] of 122 patients) than in the clinical management group (37 [30%] of 122 patients), with a Cochran-Mantel-Haenszel test-adjusted risk difference of 16·1% (95% CI 3·9-28·3; p=0·010). 105 (86%) of 122 patients in the tight control group and 100 (82%) of 122 patients in the clinical management group reported treatment-emergent adverse events; no treatment-related deaths occurred. The most common adverse events were nausea (21 [17%] of 122 patients), nasopharyngitis (18 [15%]), and headache (18 [15%]) in the tight control group, and worsening Crohn's disease (35 [29%] of 122 patients), arthralgia (19 [16%]), and nasopharyngitis (18 [15%]) in the clinical management group. INTERPRETATION: CALM is the first study to show that timely escalation with an anti-tumour necrosis factor therapy on the basis of clinical symptoms combined with biomarkers in patients with early Crohn's disease results in better clinical and endoscopic outcomes than symptom-driven decisions alone. Future studies should assess the effects of such a strategy on long-term outcomes such as bowel damage, surgeries, hospital admissions, and disability. FUNDING: AbbVie.
650    _2
$a adalimumab $x terapeutické užití $7 D000068879
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a antirevmatika $x terapeutické užití $7 D018501
650    _2
$a azathioprin $x terapeutické užití $7 D001379
650    _2
$a C-reaktivní protein $x imunologie $7 D002097
650    _2
$a Crohnova nemoc $x farmakoterapie $x imunologie $7 D003424
650    _2
$a management nemoci $7 D019468
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glukokortikoidy $x terapeutické užití $7 D005938
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prednison $x terapeutické užití $7 D011241
650    _2
$a indukce remise $7 D012074
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Panaccione, Remo $u Inflammatory Bowel Disease Unit, Department of Medicine, University of Calgary, Calgary, AB, Canada.
700    1_
$a Bossuyt, Peter $u Imelda General Hospital, Bonheiden, Belgium.
700    1_
$a Lukas, Milan $u Clinical and Research Centre for Inflammatory Bowel Disease, ISCARE Clinical Centre, Prague, Czech Republic; First Medical Faculty, Charles University, Prague, Czech Republic.
700    1_
$a Baert, Filip $u AZ Delta, Roeselare-Menen, Belgium.
700    1_
$a Vaňásek, Tomas $u Hepato-Gastroenterologie HK, sro, Hradec Králové, Czech Republic.
700    1_
$a Danalioglu, Ahmet $u Department of Gastroenterology, Bezmialem Vakif University, Istanbul, Turkey.
700    1_
$a Novacek, Gottfried $u Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
700    1_
$a Armuzzi, Alessandro $u Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy.
700    1_
$a Hébuterne, Xavier $u Service de Gastro-entérologie et Nutrition Clinique, Nice, France; Université de Nice-Sophia-Antipolis, Nice, France.
700    1_
$a Travis, Simon $u Oxford University Hospitals, Oxford, UK.
700    1_
$a Danese, Silvio $u Department of Biomedical Sciences, Humanitas University, Milan, Italy; Humanitas Clinical and Research Centre, Milan, Italy.
700    1_
$a Reinisch, Walter $u Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
700    1_
$a Sandborn, William J $u Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
700    1_
$a Rutgeerts, Paul $u Department of Gastroenterology, University of Leuven, Leuven, Belgium.
700    1_
$a Hommes, Daniel $u Department of Medicine, University of California, Los Angeles, CA, USA.
700    1_
$a Schreiber, Stefan $u Department of Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany.
700    1_
$a Neimark, Ezequiel $u AbbVie Inc, North Chicago, IL, USA.
700    1_
$a Huang, Bidan $u AbbVie Inc, North Chicago, IL, USA.
700    1_
$a Zhou, Qian $u AbbVie Inc, North Chicago, IL, USA.
700    1_
$a Mendez, Paloma $u AbbVie Spain SLU, Madrid, Spain.
700    1_
$a Petersson, Joel $u AbbVie Inc, North Chicago, IL, USA.
700    1_
$a Wallace, Kori $u AbbVie Inc, North Chicago, IL, USA.
700    1_
$a Robinson, Anne M $u AbbVie Inc, North Chicago, IL, USA.
700    1_
$a Thakkar, Roopal B $u AbbVie Inc, North Chicago, IL, USA.
700    1_
$a D'Haens, Geert $u Academic Medical Center, Amsterdam, Netherlands.
773    0_
$w MED00010161 $t Lancet (London, England) $x 1474-547X $g Roč. 390, č. 10114 (2018), s. 2779-2789
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29096949 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180418101427 $b ABA008
999    __
$a ok $b bmc $g 1287767 $s 1007094
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 390 $c 10114 $d 2779-2789 $e 20171031 $i 1474-547X $m Lancet $n Lancet $x MED00010161
LZP    __
$a Pubmed-20180404
Back

Find record

Citation metrics

Archiving options